Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
New acute lymphoblastic leukemia study findings have been reported from Oregon Health & Science University
May 4th, 2008
" The event-free survival (EFS) of children with standard-risk acute lymphoblastic leukemia (SR-ALL) is now more than 80%. However, prognosis after relapse continues to be poor," scientists writing in the Journal of Clinical Oncology report. "We examined postrelapse outcomes of children initially treated on the Children's Cancer Group CCG-1952 study. Patients and Methods We evaluated outcomes after bone marrow (BM) relapse and isolated extramedullary (EM) relapse for 347 patients with SR-ALL (WBC < 50,000/mu L; age, 1 to 9 years). The prognostic significance of several factors for EFS after relapse (EFS2) was assessed by Cox regression analysis. Stem-cell...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
